Published in AIDS Weekly, November 5th, 2001
"These latest contracts reconfirm our position as a preferred partner to the pharmaceutical industry in determining the resistance profiles of their new drugs," commented Paul Stoffels, MD, chairman of Tibotec-Virco. "We are very pleased to be working with the pharmaceutical industry as a whole to bring new improved treatments to people living with HIV/AIDS."
The latest contract with DuPont Pharmaceuticals is to establish the resistance profile of their novel second-generation non-nucleoside reverse...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.